Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies
NEW YORK, Dec. 31, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies
http://www.reportlinker.com/p01054398/Competitor-Analysis-Biosimilar-and-Biosuperior-Therapeutic-Antibodies.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical
Product description
The present Competitive Intelligence Report about Biosimilar and Biosuperior Therapeutic Antibodiesprovides a competitor evaluation in the field of recombinant monoclonal and polyclonal antibodies in the market, in the pipeline as next generation products and as biosimilar versions as of December 2012. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Marketed antibodies are attractive for companies to create next generation variants and biosimilar copies because they represent clinically and commercially validated products. New technologies such as Fc engineering, polyclonal mixtures, antibody drug conjugates or bispecific molecules as well as the expiration of patents stimulate the discovery and development of biosimilar and biosuperior/biobetter molecules. The cumulated sales volume of therapeutic antibodies for which biosmilar antibodies are in the R&D pipeline was as high as US$ 54.7 bln in the year 2011 with double digit growth rates of many representative of them:
Rituxan/MabThera
Arzerra
Erbitux
Vectibix
Herceptin
Avastin
Lucentis
Enbrel
Remicade
Humira
Cimzia
Simponi
Actemra/RoActemra
ReoPro
Campath
Orencia
Tysabri
Xolair
Synagis
Prolia/Xgeva
Soliris
Stelara
Zenapax
More than 140 biosimilar antibodies are in the pipeline with the first molecules approved in non-regulated markets. Ther regulation of the development of biosimilar antibodies in the European Union has facilitated the submission of an MAA of a first biosimilar antibody from a Korean company.
The report includes a compilation of currently active projects in research and development of biosimilar and biosuperior antibodies against commercially and clinically validated targets:
CD20
Her2
VEGF
TNF
EGF-R
CD52
GPIIb/IIIa
B7.1/B7.2 (CD80/CD86)
IL-6R
Alpha4/beta1/7 integrin
IgE
RSV
RANKL
Complement C5
IL-12/IL-23
CD25 (IL-2R)
Competitor projects are listed in a tabular format providing information on:
-Drug Codes,
-Target / Mechanism of Action,
-Class of Compound,
-Company,
-Product Category,
-Indication,
-R&D Stage and
-additional comments with a hyperlink leading to the source of information.
About Competitor Analysis Series:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
Table of Contents
CD20 Antibodies
1. Marketed CD20 Antibodies & Sales
Rituxan/MabThera Pipeline & Sales
Arzerra Pipeline & Sales
Zevalin Pipeline & Sales
Bexxar
2. Biosuperior CD20 Antibodies
Bispecific CD20 Antibodies
3. Biosimilar CD20 Antibodies
Rituximab (Erbitux) Biosimilars
Ofatumumab (Arzerra) Biosimilars
EGF-R Antibodies
1. Marketed EGF-R Antibodies & Sales
Erbitux Pipeline & Sales
Vectibix Pipeline & Sales
Nimotuzumab Pipeline
2. Biosuperior EGF-R Antibodies
3. Biosimilar EGF-R Antibodies
Cetuximab (Erbitux) Biosimilars
Panitumumab (Vectibix) Biosimilars
Her2 Antibodies
1. Marketed Her2 Antibodies & Sales
Herceptin Pipeline & Sales
Next Generation Herceptin: Pertuzumab Pipeline
2. Biosuperior Her2 Antibodies
T-DM1 Pipeline
Other Her2 Antibody-Drug Conjugates
Her2 Bispecific Antibodies
Engineered Her2 Antibodies
Imaging Her2 Antibodies
3. Biosimilar Her2 Antibodies
Trastuzumab (Herceptin) Biosimilars
VEGF Antibodies: Avastin
1. Marketed VEGF Antibody & Sales
Avastin Pipeline & Sales
2. Biosuperior VEGF Antibodies
Anti-VEGF Antibody Pipeline
Anti-VEGF-R Antibody Pipeline
Bispecific Anti-VEGF Pipeline
3. Biosimilar VEGF Antibodies
Bevacizumab (Avastin) Biosimilars
VEGF Antibodies: Lucentis
1. Marketed VEGF Antibody & Sales
Lucentis Pipeline & Sales
2. Biosuperior VEGF Antibodies
Next Generation Lucentis Pipeline
3. Biosimilar VEGF Antibodies
Ranibizumab (Lucentis) Biosimilars
TNF Antibodies
1. Marketed TNF Antibodies & Sales
Enbrel Pipeline & Sales
Remicade Pipeline & Sales
Humira Pipeline & Sales
Cimzia Pipeline & Sales
Simponi Pipeline & Sales
2. Biosuperior TNF Antibodies
Biosuperior TNF Antibodies
3. Biosimilar Her2 Antibodies
Etanercept (Enrel) Biosimilars
Infliximab (Remicade) Biosimilars
Adalimumab (Humira) Biosimilars
Certolizumab pegol (Cimzia) Biosimilars
Golimumab (Simponi) Biosimilars
IL-6R Antibodies
1. Marketed IL-6R Antibody & Sales
Actemra Pipeline & Sales
2. Biosuperior IL-6R Antibodies
Biosuperior IL-6R Antibodies
3. Biosimilar VEGF Antibodies
Tocilizumab (Actemra) Biosimilars
GPIIb/IIIa Antibodies
1. Marketed GPIIb/IIIa Antibody & Sales
ReoPro Pipeline & Sales
2. Biosimilar GPIIb/IIIa Antibodies
Abciximab (ReoPro) Biosimilars
CD52 Antibodies
1. Marketed CD52 Antibody
Campath Pipeline & Sales
2. Biosimilar CD52 Antibodies
Alemtuzumab (Campath) Biosimilars
CD80/CD86 (B7.1/B7.2) Antibodies
1. Marketed CD80/86 (B7-1/B7-2) Antibodies & Sales
Orencia Pipeline & Sales
2. Biosuperior CD80/86 (B7-1/B7-2) Antibodies
Biosuperior CD80/86 (B7-1/B7-2) Antibodies
3. Biosimilar CD80/86 (B7-1/B7-2) Antibodies
Abatacept (Orencia) Biosimilars
Alpha4/beta1/7 Integrin Antibodies
1. Marketed Alpha4/beta1/7 Integrin Antibody
Tysabri Pipeline & Sales
2. Biosimilar Alpha4/beta1/7 Integrin Antibodies
Natalizumab (Tysabri) Biosimilars
IgE Antibodies
1. Marketed IgE Antibodies & Sales
Xolair Pipeline & Sales
2. Biosuperior IgE Antibodies
Biosuperior IgE Antibodies
3. Biosimilar IgE Antibodies
Omalizumab (Xolair) Biosimilars
RSV Antibodies
1. Marketed RSV Antibodies & Sales
Synagis Pipeline & Sales
2. Biosuperior RSV Antibodies
Biosuperior RSV Antibodies
3. Biosimilar RSV Antibodies
Palivizumab (Synagis) Biosimilars
RANKL Antibodies
1. Marketed RANKL Antibodies & Sales
Prolia/XGEVA Pipelines & Sales
2. Biosuperior RANKL Antibodies
Biosuperior RANKL Antibodies
3. Biosimilar RANKL Antibodies
Denosumab (Prolia / XGEVA) Biosimilars
Complement C5 Antibodies
1. Marketed Complement C5 Antibodies & Sales
Soliris Pipelines & Sales
2. Biosuperior Complement C5 Antibodies
Biosuperior Complement C5 Antibodies
3. Biosimilar Complement C5 Antibodies
Eculizumab (Soliris) Biosimilars
IL-12/IL-23 Antibodies
1. Marketed IL-12/IL-23 Antibody
Stelara Pipeline & Sales
2. Biosimilar IL-12/IL-23 Antibodies
Ustekinumab (Stelara) Biosimilars
CD25 (IL-2R) Antibodies
1. Marketed CD25 (IL-2R) Antibodies
Zenapax Pipeline
2. Biosuperior CD25 (IL-2R) Antibodies
Biosuperior CD25 (IL-2R) Antibodies
3. Biosimilar CD25 (IL-2R) Antibodies
Daclizumab (Zenapax) Biosimilars
To order this report:
Biopharmaceutical Industry: Competitor Analysis: Biosimilar and Biosuperior Therapeutic Antibodies
Contact Nicolas: [email protected]
US: (805)-652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article